report result market close novemb
compani host confer call webcast
investor mylan com id
lower ep estim slightli
consensu estim full-year estim
vs consensu near midpoint
revis ep guidanc rang recal earn
lower revenu ep guidanc revenu
prior estim ep
guidanc prior
accord iqvia appear total us prescript
juli august
septemb data yet avail similarli us gener
prescript declin july/august us brand declin
yoy respect us seem myl yoy declin
intensifi accord prescript sale data iqvia see
tabl insid detail accord prescript data
iqvia week end copaxon
approxim new prescript nrx share
approxim end june
gener advair restasi still
approv fda earn call mylan ceo heather
bresch indic compani get advair approv ahead
goal date mid-octob current model
advair sale million given lengthi delay
product deterior advair sale likelihood
author gener think opportun also rapidli
diminish previous indic guidanc includ
risk adjust launch remov advair restasi
assumpt result lower ep estim
disclos issu august enter
agreement purchas world-wide right
commerci product approxim million
mention agreement confer call later came
bought world-wide right novarti cystic fibrosi product tobi
podhal tobramycin inhal powder tobi tobramycin
solut inhal iqvia report ttm sale million
tobi hope result explain deal whether
accret impact guidanc might
myl board announc august board form
strateg review committe evalu altern unlock valu
sinc stock under-perform
share under-perform past month
vs well ytd year year
year period maintain market perform rate
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap ep exclud one-tim item includ restructur
compani data secur llc estim reuter
thing look mylan call
organ grow year north america grow
deal tobi acquisit ttm sale deal accret
much
updat impact epipen shortag epipen gener vs
time potenti impact advair restasi gener
updat potenti manufactur issu us mani product
manufactur delay point
potenti manag chang investor rais issu discount teva
share perform relat manag creat depress multipl
given share under-perform would interest manag think
drive under-perform
updat price fix litig
us european price environ review
updat biosimilar pipelin
million unless otherwis note
factset iqvia secur llc
factset iqvia secur llc
factset iqvia secur llc
million unless otherwis note
compani file secur llc estim
mylan incom segment revenu north rest chg segment revenu north rest profit expens expens interest incom incom incom per specialti pharmaceut
price target nc
dcf-deriv price target base discount rate termin ev/ebitda multipl
risk includ gener drug market dynam like less favor prior
year gener compani may less polit cover go forward gener drug
penetr may alreadi peak epipen concentr sale profit govern risk
sec investig lawsuit integr risk tie meda deal
remain market perform believ face anoth potenti headwind gener a/b
rate epipen emerg believ like also believ gener sector
rapid margin-declin environ caution warrant
mylan inc base canonsburg pa domicil netherland among world
largest gener pharmaceut compani engag develop licens manufactur
market distribut gener proprietari pharmaceut product primari specialti
pharma product epipen treatment acut allerg reaction
